Bioavailability of Herbal Products: Approach Toward Improved Pharmacokinetics: Approach Toward Improved Pharmacokinetics

Evidence-Based Validation of Herbal Medicine

Volumn , Issue , 2015, Pages 218-245

  Mukherjee, Pulok K ^a   Harwansh, Ranjit K ^a   Bhattacharyya, Sauvik ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Bioavailability; Biological half life; Herbal drug; Nanoemulsion; Nanotechnology; Novel drug delivery system; Pharmacokinetics; Phospholipid based complex system; Phytopharmaceuticals; Phytosome

Indexed keywords

BIOCHEMISTRY; BIOGRAPHIES; LIPOSOMES; NANOTECHNOLOGY; PHARMACOKINETICS; PHOSPHOLIPIDS; TARGETED DRUG DELIVERY;

BIOAVAILABILITY; DRUG DELIVERY SYSTEM; HALF LIVES; HERBAL DRUG; NANOEMULSION; PHYTOPHARMACEUTICALS; PHYTOSOME;

CONTROLLED DRUG DELIVERY;

EID: 84940063807     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-800874-4.00010-6     Document Type: Chapter

References (137)

1. Rahman M.A., Harwansh R., Mirza M.A., Hussain S., Hussain A. Oral lipid based drug delivery system (LBDDS): formulation, characterization and application: a review. Curr Drug Deliv 2011, 8:1-16.
2. Kesarwani K., Gupta R. Bioavailability enhancers of herbal origin: an overview. Asian Pac J Trop Biomed 2013, 3:253-266.
3. Mukherjee P.K., Venkatesh M., Maiti K., Mukherjee K., Saha B.P. Value added herbal drug delivery systems-perspectives and developments. Indian J Pharm Educ Res 2009, 43:329-337.
4. Ajazuddin S.S. Applications of novel drug delivery system for herbal formulations. Fitoterapia 2010, 81:680-689.
5. Li Y., Zheng J., Xiao H., McClements D.J. Nanoemulsion-based delivery systems for poorly water-soluble bioactive compounds: influence of formulation parameters on polymethoxyflavone crystallization. Food Hydrocolloids 2012, 27:517-528.
6. Silva H.D., Cerqueira M.Â., Vicente A.A. Nanoemulsions for food applications: development and characterization. Food Bioprocess Technol 2012, 5:854-867.
7. Sessa M., Balestrieri M.L., Ferrari G., Servillo L., Castaldo D., D'Onofrio N., et al. Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems. Food Chem 2014, 147:42-50.
8. Aqil F., Munagala R., Jeyabalan J., Vadhanam M.V. Bioavailability of phytochemicals and its enhancement by drug delivery Systems. Cancer Lett 2013, 334:133-141.
9. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46:3-26.
10. Huang Q., Yu H., Ru Q. Bioavailability and delivery of nutraceuticals using nanotechnology. J Food Sci 2010, 75:R50-R57.
11. Brown J.E., Khodr H., Hider R.C., Rice-Evans C.A. Structural dependence of flavonoid interactions with Cu21 ions: implications for their antioxidant properties. Biochem J 1998, 330:1173-1178.
12. Walle T. Absorption and metabolism of flavonoids. Free Radical Biol Med 2004, 36:829-837.
13. Espín J.C., García-Conesa M.T., Tomás-Barberán F.A. Nutraceuticals: facts and fiction. Phytochemistry 2007, 68:2986-3008.
14. Passamonti S., Terdoslavich M., Franca R., Vanzo A., Tramer F., Braidot E., et al. Bioavailability of flavonoids: a review of their membrane transport and the function of bilitranslocase in animal and plant organisms. Curr Drug Metab 2009, 10:369-394.
15. Hollman P.C., Bijsman M.N., VanGameren Y., Cnossen E.P., DeVries J.H., Katan M.B. The sugar moiety is a major determinant of the absorption of dietary flavonoid glycosides in man. Free Radical Res 1999, 31:569-573.
16. Harborne J.B. The flavonoids: advances in research since 1986 1994, Chapman & Hall, London, UK.
17. Scalbert A., Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr 2000, 130:2073S-2085S.
18. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004, 32:1377-1382.
19. Wenzel E., Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005, 49:472-481.
20. Bhattaram V.A., Graefe U., Kohlert C., Veit M., Derendorf H. Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine 2002, 9:1-33.
21. Fourtillan J.B., Brisson A.M., Girault J., Ingrand I., Decourt J.P., Drieu K., et al. Pharmacokinetic properties of bilobalide and ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761). Therapie 1995, 50:137-144.
22. Kleijnen J., Knipschild P. Ginkgo biloba. Lancet 1992, 340:1136-1139.
23. Biber A., Koch E. Bioavailability of ginkgolides and bilobalide from extracts of Ginkgo biloba using GC/MS. Planta Med 1999, 65:192-193.
24. Biber A., Fischer H., Römer A., Chatterjee S.S. Oral bioavailability of hyperforin from Hypericum extracts in rats and human volunteers. Pharmacopsychiatry 1998, 31:36-43.
25. Staffeldt B., Kerb R., Brockmöller J., Ploch M., Roots I. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the Hpericum perforatum extract LI 160 in healthy volunteers. J Geriatr Psychiatry Neurol 1994, 1:S47-S53.
26. Fox E., Murphy R.F., McCully C.L., Adamson P.C. Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. Cancer Chemother Pharmacol 2001, 47:41-44.
27. Yoshikawa M., Murakami T., Yamahara J., Matsuda H. Bioactive saponins and glycosides: XII. Horse chestnut. (2) Structures of escins IIIb, IV, V, and VI and isoescins Ia, Ib, and V, acylated polyhydroxyoleanene triterpene oligoglycosides, from the seeds of horse chestnut tree (Aesculus hippocastanum L. Hippocastanaceae). Chem Pharm Bull 1998, 46:1764-1769.
28. Loew D., Schrodter A., Schwankl W., Marz R.W. Measurement of the bioavailability of aescin-containing extracts. Methods Find Exp Clin Pharmacol 2000, 22:537-542.
29. Lang W., Mennicke W.H. Pharmacokinetic studies on tritiated aescin in the mouse and rat. Arzneimittelforschung 1972, 22:1928-1932.
30. Steinegger E., Hövel H. Analytische und biologische untersuchungen an saliceen-wirkstoffen, insbesondere an salicin: i. identifizierungs-, isolierungs- und bestimmungsmethoden. Pharm Acta Helv 1972, 47:133-141.
31. Pentz R., Busse H.G., König R., Sioegers C.P. Bioavailability of salicylic acid and caffeine from a combination preparation phytoanalgetischen Lübeck, Med Univ, Diss 1989.
32. Schmid B., Kötter I., Heide L. Pharmacokinetics of salicin after oral administration of a standardised willow bark extract. Eur J Clin Pharmacol 2001, 57:387-391.
33. Weyhenmeyer R., Mascher H., Birkmayer J. Study on dose-linearity of the pharmacokinetics of silibin diastereomers using a new stereospecific assay. Int J Clin Pharmacol Ther Toxicol 1992, 30:134-138.
34. Erlund I., Kosonen T., Alfthan G., Maenpaa J., Perttunen K., Kenraali J., et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 2000, 56:545-553.
35. Graefe E.U., Wittig J., Mueller S., Riethling A.K., Uehleke B., Drewelow B., et al. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 2001, 41:492-499.
36. Morand C., Manach C., Crespy V., Remesy C. Respective bioavailability of quercetin aglycone and its glycosides in a rat model. Biofactors 2000, 12:169-174.
37. Suo X.B., Zhang H., Wang Y.Q. HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. Biomed Chromatogr 2007, 21:730-734.
38. Ye L., Wang T., Tang L., Liu W., Yang Z., Zhou J., et al. Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P glycoprotein. J Pharm Sci 2011, 100:5007-5017.
39. Delmas D., Aires V., Limagne E., Dutartre P., Mazué F., Ghiringhelli F., et al. Transport, stability, and biological activity of resveratrol. Ann N Y Acad Sci 2011, 1215:48-59.
40. Goldberg D.M., Yan J., Soleas G.J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003, 36:79-87.
41. Boocock D.J., Faust G.E., Patel K.R., Schinas A.M., Brown V.A., Ducharme M.P., et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007, 16:1246-1252.
42. Brown V.A., Patel K.R., Viskaduraki M., Crowell J.A., Perloff M., Booth T.D., et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010, 70:9003-9011.
43. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharmaceutics 2007, 4:807-818.
44. Holder G.M., Plummer J.L., Ryan A.J. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6- heptadiene-3,5-dione) in the rat. Xenobiotica 1978, 8:761-768.
45. Wahlstrom B., Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol 1978, 43:86-92.
46. Ravindranath V., Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology 1980, 16:259-265.
47. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998, 64:353-356.
48. Pan M.H., Huang T.M., Lin J.K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999, 27:486-494.
49. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 10:6847-6854.
50. Marczylo T.H., Verschoyle R.D., Cooke D.N., Morazzoni P., Steward W.P., Gescher A.J. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 2007, 60:171-177.
51. Yang K.Y., Lin L.C., Tseng T.Y., Wang S.C., Tsai T.H. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Anal Technol Biomed Life Sci 2007, 853:183-189.
52. Bhattacharyya S., Ahmmed S.M., Saha B.P., Mukherjee P.K. Soya phospholipid complex of mangiferin enhances its hepatoprotectivity by improving its bioavailability and pharmacokinetics. J Sci Food Agric 2014, 94:1380-1388.
53. Han D., Chen C., Zhang C., Zhang Y., Tang X. Determination of mangiferin in rat plasma by liquid-liquid extraction with UPLC-MS/MS. J Pharm Biomed Anal 2010, 51:260-263.
54. Hou S., Wang F., Li Y., Li Y., Wang M., Sun D., et al. Pharmacokinetic study of mangiferin in human plasma after oral administration. Food Chem 2012, 132:289-294.
55. Zhang Y., Wang G.J., Song T.T., Murphy P.A., Hendrich S. Urinary disposition of the soybean isoflavones daidzein, genistein and glycitein differs among humans with moderate fecal isoflavone degradation activity. J Nutr 1999, 129:957-962.
56. Coldham N.G., Sauer M.J. Pharmacokinetics of [14C]genistein in the rat: gender-related differences, potential mechanisms of biological action, and implications for human health. Toxicol Appl Pharmacol 2000, 164:206-215.
57. Kwon S.H., Kang M.J., Huh J.S., Ha K.W., Lee J.R., Lee S.K., et al. Comparison of oral bioavailability of genistein and genistin in rats. Int J Pharm 2007, 337:148-154.
58. Anupongsanugool E., Teekachunhatean S., Rojanasthien N., Pongsatha S., Sangdee C. Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women. BMC Clin Pharmacol 2005, 3:5--2.
59. Murugan V., Mukherjee K., Maiti K., Mukherjee P.K. Enhanced oral bioavailability and antioxidant profile of ellagic acid by phospholipids. J Agric Food Chem 2009, 57:4559-4565.
60. Stoner G.D., Sardo C., Apseloff G., Mullet D., Wargo W., Pound V., et al. Pharmacokinetics of anthocyanins and ellagic acid in healthy volunteers fed freeze-dried black raspberries daily for 7 days. J Clin Pharmacol 2005, 45:1153-1164.
61. Seeram N.P., Lee R., Heber D. Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta 2004, 348:63-68.
62. Bhattacharyya S., Ahammed S.M., Saha B.P., Mukherjee P.K. The gallic acid-phospholipid complex improved the antioxidant potential of gallic acid by enhancing its bioavailability. AAPS PharmSciTech 2013, 14:1025-1033.
63. Gao S., Zhan Q., Li J., Yang Q., Li X., Chen W., et al. LC-MS/MS method for the simultaneous determination of ethyl gallate and its major metabolite in rat plasma. Biomed Chromatogr 2010, 24:472-478.
64. Ferruzzi M.G., Lobo J.K., Janle E.M., Cooper B., Simon J.E., Wu Q.L., et al. Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease. J Alzheimers Dis 2009, 18:113-124.
65. Konishi Y., Kobayashi S. Transepithelial transport of chlorogenic acid, caffeic acid, and their colonic metabolites in intestinal caco-2 cell monolayers. J Agric Food Chem 2004, 5:2518-2526.
66. Chen W.C., Liou S.S., Tzeng T.F., Lee S.L., Liu I.M. Effect of topical application of chlorogenic acid on excision wound healing in rats. Planta Med 2013, 79:616-621.
67. Ren J., Jiang X., Li C. Investigation on the absorption kinetics of chlorogenic acid in rats by HPLC. Arch Pharmacal Res 2007, 30:911-916.
68. Yang H., Yuan B., Li L., Chen H., Li F. HPLC determination and pharmacokinetics of chlorogenic acid in rabbit plasma after an oral dose of Flos Lonicerae extract. J Chromatogr Sci 2004, 42:173-176.
69. Qin S.H., Liu H.G. Pharmacokinetics study on yinhuang compound microenema in rabbits. Zhongguo Zhongyao Zazhi 2006, 31:54-56.
70. Sultana S., Verma K., Khan R. Nephroprotective efficacy of chrysin against cisplatin-induced toxicity via attenuation of oxidative stress. J Pharm Pharmacol 2012, 64:872-881.
71. Walle T., Otake Y., Brubaker J.A., Walle U.K., Halushka P.V. Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol 2001, 51:143-146.
72. Tong L., Wan M., Zhang L., Zhu Y., Sun H., Bi K. Simultaneous determination of baicalin, wogonoside, baicalein, wogonin, oroxylin A and chrysin of Radix scutellariae extract in rat plasma by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 2012, 70:6-12.
73. Zhu Y., Tong L., Zhou S., Sun H., Bi K., Zhang Boli Simultaneous determination of active flavonoids and alkaloids of Tang-Min-Ling-Pill in rat plasma by liquid chromatography tandem mass Spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2012, 904:51-58.
74. Melo C.L.L.D., Queiroz M.G.R., Filho A.C.V.A., Rodrigues A.M., Sousa D.F.D., Almeida J.G.L., et al. Betulinic acid, a natural pentacyclic triterpenoid, prevents abdominal fat accumulation in mice fed a high-fat diet. J Agric Food Chem 2009, 57:8776-8781.
75. Udeani G.O., Zhao G.M., Shin Y.G., Cooke B.P., Graham J., Beecher C.W.W., et al. Pharmacokinetics and tissue distribution of betulinic acid in CD-1 mice. Biopharm Drug Dispos 1999, 20:379-383.
76. Rahman M.A., Hussain A., Iqbal Z., Harwansh R.K., Singh L.R., Ahmad S. Nanosuspension: a potential nanoformulation for improved delivery of poorly bioavailable drug. Micro Nanosyst 2013, 5:273-287.
77. Mishra B., Patel B.B., Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 2010, 6:9-24.
78. Braithwaite M.C., Tyagi C., Tomar L.K., Kumar P., Choonara Y.E., Pillay V. Nutraceutical-based therapeutics and formulation strategies augmenting their efficiency to complement modern medicine: an overview. J Funct Foods 2014, 68:2-99.
79. El-Samaligy M.S., Afifi N.N., Mahmoud E.A. Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance. Int J Pharm 2006, 319:121-129.
80. Benson H.A.E. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv 2005, 2:23-33.
81. Bavarsad N., Bazzaz B.S.F., Khamesipour A., Jaafari M.R. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice. Acta Trop 2012, 124:33-41.
82. Mahale N.B., Thakkar P.D., Mali R.G., Walunj D.R., Chaudhari S.R. Niosomes: novel sustained release nonionic stable vesicular systems-an overview. Adv Colloid Interface Sci 2012, 183:46-54.
83. Junyaprasert V.B., Singha P., Suksiriworapong J., Chantasart D. Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid. Int J Pharm 2012, 423:303-311.
84. Paolino D., Lucania G., Mardente D., Alhaique F., Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J Controlled Release 2005, 106:99-110.
85. Jain N.K., Gupta U. Application of dendrimer-drug complexation in the enhancement of drug solubility and bioavailability. Expert Opin Drug Metab Toxicol 2008, 4:1035-1052.
86. Abderrezak A., Bourassa P., Mandeville J.S., Sedaghat-Herati R., Tajmir-Riahi H.A. Dendrimers bind antioxidant polyphenols and cisplatin drug. PLoS ONE 2012, 7:1-12.
87. Tiyaboonchai W., Tungpradit W., Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanaparticles. Int J Pharm 2007, 337:299-306.
88. Arica Y.B., Benoit J.P., Lamprecht A. Paclitaxel-loaded lipid nanoparticles. Drug Dev Ind Pharm 2006, 32:1089-1094.
89. Mainardes R.M., Evangelista R.C. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 2005, 290:137-144.
90. Das S., Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011, 12:62-76.
91. Wang D., Wang X., Li X., Ye L. Preparation and characterization of solid lipid nanoparticles loaded with α-asarone. PDA J Pharm Sci Technol 2008, 62:56-65.
92. Hu L., Jia H., Luo Z., Liu C., Xing Q. Improvement of digoxin oral absorption in rabbits by incorporation into solid lipid nanoparticles. Pharmazie 2010, 65:110-113.
93. Li H., Zhao X., Ma Y., Zhai G., Li L., Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Controlled Release 2009, 133:238-244.
94. Harwansh R.K., Patra K.C., Pareta S.K. Nanoemulsion as potential vehicles for transdermal delivery of pure phytopharmaceuticals and poorly soluble drug. Int J Drug Delivery 2011, 3:209-218.
95. Harwansh R.K., Patra K.C., Pareta S.K., Singh J., Rahman M.A. Nanoemulsions as vehicles for transdermal delivery of glycyrrhizin. Braz J Pharm Sci 2011, 47:769-778.
96. Porter C.J.H., Pouton C.W., Cuine J.F., Charman W.N. Enhancing intestinal drug solubilization using lipid-based delivery systems. Adv Drug Delivery Rev 2008, 60:673-691.
97. Choudhury H., Gorain B., Karmakar S., Biswas E., Dey G., Barik R., et al. Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform. Int J Pharm 2014, 460:131-143.
98. Mikhail A.S., Allen C. Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels. J Controlled Release 2009, 138:214-223.
99. Hamaguchi T., Matsumura Y., Suzuki M., Shimizu K., Goda R., Nakamura I., et al. NK105, a paclitaxel incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 2005, 92:1240-1246.
100. Kidd P.M. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev 2009, 14:226-246.
101. Freag M.S., Elnaggar Y.S.R., Abdallah O.Y. Lyophilized phytosomal nanocarriers as platforms for enhanced diosmin delivery: optimization and ex vivo permeation. Int J Nanomed 2013, 8:2385-2397.
102. Maiti K., Mukherjee K., Gantait A., Saha B.P., Mukherjee P.K. Enhanced therapeutic potential of naringenin-phospholipid complex in rats. J Pharm Pharmacol 2006, 58:1227-1233.
103. Maiti K., Mukherjee K., Murugan V., Saha B.P., Mukherjee P.K. Enhancing bioavailability and hepatoprotective activity of andrographolide from Andrographis paniculata, a well-known medicinal food, through its herbosome. J Sci Food Agric 2010, 90:43-51.
104. Hüsch J., Bohnet J., Fricker G., Skarke C., Artaria C., Appendino G., et al. Enhanced absorption of boswellic acids by a lecithin delivery form (Phytosome®) of Boswellia extract. Fitoterapia 2013, 84:89-98.
105. Maiti K., Mukherjee K., Gantait A., Ahamed K.F.H., Saha B.P., Mukherjee P.K. Enhanced therapeutic benefit of quercetin-phospholipid complex in carbon tetrachloride-induced acute liver injury in rats: a comparative study. Iran J Pharmacol Ther 2005, 4:84-90.
106. Maiti K., Mukherjee K., Gantait A., Saha B.P., Mukherjee P.K. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 2007, 330:155-163.
107. Mukherjee K., Venkatesh M., Venkatesh P., Saha B.P., Mukherjee P.K. Effect of soy phosphatidyl choline on the bioavailability and nutritional health benefits of resveratrol. Food Res Int 2011, 44:1088-1093.
108. Pifferi G. Silipide: a new bioavailable complex of silybin. Planta Med 1991, 57:A12.
109. Semalty A., Semalty M., Riwat M.S.M., Franceschi F. Supramolecular phospholipids-polyphenolics interaction: the PHYTOSOME® strategy to improve the bioavailability of phytochemicals. Fitoterapia 2010, 81:306-314.
110. Hüsch J., Dutagaci B., Glaubitz C., Geppert T., Schneider G., Harms M., et al. Structural properties of so-called NSAID-phospholipid-complexes. Eur J Pharm Sci 2011, 44:103-116.
111. Mauri P., Simonetti P., Gardana C., Minoggio M., Morazzoni P., Bombardelli E., et al. Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts. Rapid Commun Mass Spectrom 2001, 15:929-934.
112. Gatti G., Perucca E. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. Int J Clin Pharmacol Ther 1994, 32:614-617.
113. Savio D., Harrasser P.C., Basso G. Softgel capsule technology as an enhancer device for the absorption of natural principles in humans, a bioavailability cross-over randomised study on silybin. Arzneimittelforschung 1998, 48:1104-1106.
114. Schandalik R., Gatti G., Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung 1992, 42:964-968.
115. Liu A., Lou H., Zhao L., Fan P. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal 2006, 40:720-727.
116. Maiti K., Mukherjee K., Murugan V., Saha B.P., Mukherjee P.K. Exploring the effect of hesperetin-HSPC complex - a novel drug delivery system on the in vitro release, therapeutic efficacy and pharmacokinetics. AAPS PharmSciTech 2009, 10:943-950.
117. Jacobson J.M., Feinman L., Liebes L., Ostrow N., Koslowski V., Tobia A., et al. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis-C virus infection. Antimicrob Agents Chemother 2001, 45:517-524.
118. Brockmöller J., Reum T., Bauer S., Kerb R., Hübner W.D., Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997, 30:94-101.
119. Kerb R., Brockmöller J., Staffeldt B., Ploch M., Roots I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996, 40:2087-2093.
120. Howells L.M., Berry D.P., Elliott P.J., Jacobson E.W., Hoffmann E., Hegarty B., et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res 2011, 4:1419-1425.
121. Amiot M.J., Romier B., Dao T.M., Fanciullino R., Ciccolini J., Burcelin R., et al. Optimization of trans-Resveratrol bioavailability for human therapy. Biochimie 2013, 95:1233-1238.
122. Muzzio M., Huang Z., Hu S.C., Johnson W.D., McCormick D.L., Kapetanovic I.M. Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs. J Pharm Biomed Anal 2012, 59:201-208.
123. Liang L., Liu X., Wang Q., Cheng S., Zhang S., Zhang M. Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3,5,4'-tri-O-acetylresveratrol in rats. Phytomedicine 2013, 20:558-563.
124. Zhang J., Tang Q., Xu X., Li N. Development and evaluation of a novel phytosome-loaded chitosan microsphere system for curcumin delivery. Int J Pharm 2013, 448:168-174.
125. Arya P., Pathak K. Assessing the viability of microsponges as gastro retentive drug delivery system of curcumin: optimization and pharmacokinetics. Int J Pharm 2014, 460:1-12.
126. He B., Li Q., Jia Y., Zhao L., Xiao F., Lv C., et al. A UFLC-MS/MS method for simultaneous quantitation of spinosin, mangiferin and ferulic acid in rat plasma: application to a comparative pharmacokinetic study in normal and insomnic rats. J Mass Spectrom 2012, 47:1333-1340.
127. Cai F., Xu W., Wei H., Sun L., Gao S., Yang Q., et al. Simultaneous determination of active xanthone glycosides, timosaponins and alkaloids in rat plasma after oral administration of Zi-Shen Pill extract for the pharmacokinetic study by liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2010, 878:1845-1854.
128. Liu Y., Xu F., Zeng X., Yang L., Deng Y., Wu Z., et al. Application of a liquid chromatography/tandem mass spectrometry method to pharmacokinetic study of mangiferin in rats. J Chromatogr B Anal Technol Biomed Life Sci 2010, 878:3345-3350.
129. Setchell K.D., Brzezinski A., Brown N.M., Desai P.B., Melhem M., Meredith T., et al. Pharmacokinetics of a slow-release formulation of soybean isoflavones in healthy postmenopausal women. J Agric Food Chem 2005, 53:1938-1944.
130. Hou P., Zeng Y., Ma B., Wang X., Liu Z., Li L., et al. A fast, sensitive, and high-throughput method for the simultaneous quantitation of three ellagitannins from Euphorbiae pekinensis Radix in rat plasma by ultra-HPLC-MS/MS. J Sep Sci 2013, 36:2544-2551.
131. Shahrzad S., Aoyagi K., Winter A., Koyama A., Bitsch I. Pharmacokinetics of gallic acid and its relative bioavailability from tea in healthy humans. J Nutr 2001, 131:1207-1210.
132. Zhou W., Liu S., Ju W., Shan J., Meng M., Cai B., et al. Simultaneous determination of phenolic acids by UPLC-MS/MS in rat plasma and its application in pharmacokinetic study after oral administration of Flos Lonicerae preparations. J Pharm Biomed Anal 2013, 86:189-197.
133. Sun H., Dong T., Zhang A., Yang J., Yan G., Sakurai T., et al. Pharmacokinetics of hesperetin and naringenin in the Zhi Zhu Wan, a traditional Chinese medicinal formulae, and its pharmacodynamics study. Phytother Res 2013, 27:1345-1351.
134. Yang C.P., Liu M.H., Zou W., Guan X.L., Lai L., Su W.W. Toxicokinetics of naringin and its metabolite naringenin after 180-day repeated oral administration in beagle dogs assayed by a rapid resolution liquid chromatography/tandem mass spectrometric method. J Asian Nat Prod Res 2012, 14:68-75.
135. Wen J., Qiao Y., Yang J., Liu X., Song Y., Liu Z., et al. UPLC-MS/MS determination of paeoniflorin, naringin, naringenin and glycyrrhetinic acid in rat plasma and its application to a pharmacokinetic study after oral administration of Si-Ni-San decoction. J Pharm Biomed Anal 2012, 66:271-277.
136. Tong L., Zhou D., Gao J., Zhu Y., Sun H., Bi K. Simultaneous determination of naringin, hesperidin, neohesperidin, naringenin and hesperedin of Fractus aurantii extract in rat plasma by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 2012, 58:58-64.
137. Jin M.J., Kim U., Kim I.S., Kim Y., Kim D.H., Han S.B., et al. Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. J Toxicol Environ Health 2010, 73:1441-1450.